Real-world evidence (RWE) is becoming an increasingly important part of evidence generation in medicines regulation. In Europe, the Data Analysis and Real-World Interrogation Network (DARWIN EU) has moved this concept into a structured regulatory infrastructure, giving the European medicines regulatory network access to real-world healthcare data for scientific evaluation and regulatory decision-making.
The continued DARWIN EU expansion is therefore more than an increase in data sources. It represents a shift toward making high-quality, timely real-world evidence a more established part of the medicine lifecycle.
DARWIN EU is Moving RWE From Possibility to Regulatory Infrastructure
DARWIN EU was established by European Medicines Agency (EMA) and the European medicines regulatory network in 2022 to generate evidence from real-world healthcare databases. Its data partners include organisations with access to sources such as electronic health records, hospitals, primary care, health insurance databases, registries and biobanks.
The network uses a federated approach in which data partners standardise data using the OMOP Common Data Model while analyses can be performed locally. This creates a structured way to generate evidence across multiple data sources while supporting data protection requirements.
This makes DARWIN EU EMA infrastructure increasingly relevant to questions that cannot always be answered through clinical trials alone.
What has DARWIN EU Achieved So Far?
The network has expanded significantly since its establishment. According to EMA’s latest review covering February 2025 to February 2026, DARWIN EU reached 40 data partners across 18 European countries, with access to data from approximately 250 million patients, including additional US-FDA data. During the reporting period, 108 research topics were assessed, and 88 studies were completed or ongoing.
DARWIN EU studies have addressed areas including:
- Medicine safety and effectiveness
- Drug utilisation
- Disease epidemiology
- Study feasibility and design
- Public health preparedness
- Pharmacovigilance and regulatory questions
EMA reports that some studies have directly supported formal regulatory decisions, while others have strengthened clinical or methodological understanding and supported preparedness activities. The network is therefore developing from a relatively new initiative into an established evidence-generation capability within the European regulatory system.
How is DARWIN EU Changing Regulatory Decision-Making?
The value of DARWIN EU is not simply the volume of data available. Its importance lies in creating a structured pathway for converting real-world data (RWD) into usable regulatory evidence.
DARWIN EU can help regulators investigate questions relating to:
- How medicines are used in routine clinical practice
- Safety and effectiveness across patient populations
- Disease epidemiology and treatment patterns
- The feasibility of potential studies
- Evidence needed during the post-authorisation lifecycle
The resulting RWE can complement clinical trial evidence and support scientific evaluations and regulatory decisions. EMA describes DARWIN EU as a key mechanism for generating timely and reliable evidence on the use, safety and effectiveness of medicines.
For pharmaceutical companies, this means that RWE should increasingly be considered as part of the broader RWE regulatory strategy, rather than as evidence generated only after approval.
DARWIN EU is Part of a Global RWE Regulatory Shift
The growing role of DARWIN EU reflects a broader movement toward using healthcare data to answer regulatory questions throughout the medicine lifecycle.
Clinical trials remain central to demonstrating the safety and efficacy of medicines. However, real-world data can provide additional information from routine healthcare settings, helping regulators address questions that emerge across wider and more diverse patient populations.
In Europe, this development is also closely connected with the European Health Data Space (EHDS). The EHDS Regulation entered into force in March 2025 and is intended to improve access to and exchange of health data, including for secondary use. EMA identifies DARWIN EU as an important foundation for connecting the medicines regulatory network with the EHDS. Together, these developments point toward a regulatory environment where access to reliable health data and the ability to generate fit-for-purpose evidence become increasingly important.
What Does DARWIN EU Mean for Pharmaceutical Companies?
The expansion of DARWIN EU gives pharmaceutical companies a stronger reason to consider real-world evidence (RWE) earlier in development and regulatory planning. The value of RWE depends not simply on having access to real-world data (RWD), but on whether that data is relevant to the target population, sufficiently reliable and structured, and capable of answering a defined regulatory question. Sponsors therefore need to consider data availability and quality alongside study feasibility, appropriate methodology, and the intended regulatory use of the resulting evidence. When these elements are considered together, RWE can be positioned as part of a broader evidence strategy that complements clinical trial data and supports regulatory evaluation, decision-making, and product lifecycle planning.
The RWE Regulatory Evidence-Readiness Framework
A practical way to assess RWE readiness is to consider five connected elements:
This approach helps move RWE planning from a data-first exercise to a decision-focused evidence strategy.
From Real-World Data to Regulatory Decision
The growing DARWIN EU network illustrates a clear evidence pathway:
Real-World Data → Data Standardisation → Study Design → Analysis → Real-World Evidence → Regulatory Assessment
As DARWIN EU expansion continues and the European Health Data Space develops, the ability to identify, assess and strategically use RWE will become increasingly relevant to pharmaceutical companies operating in Europe.
For regulatory teams, the key consideration is therefore straightforward: RWE should be planned around the regulatory question, not added after the evidence strategy has already been defined.
How Can DDReg Help with RWE Regulatory Strategy?
As real-world evidence becomes increasingly relevant to regulatory decision-making, pharmaceutical companies need to ensure that RWE generation is aligned with specific regulatory questions and evidence requirements. DDReg supports sponsors in translating regulatory objectives into structured evidence and regulatory strategies across the product lifecycle.
Through its Regulatory Affairs Services, DDReg can support:
- RWE regulatory strategy aligned with product development and lifecycle objectives
- Regulatory gap analysis to identify where real-world evidence may complement existing clinical evidence
- Evidence and data strategy based on the intended regulatory question, target population, and market requirements
- Regulatory intelligence to monitor evolving expectations around RWE and real-world data
- eCTD Regulatory submission and lifecycle strategy, helping position relevant evidence within broader regulatory plans
By connecting regulatory questions, evidence requirements, and real-world data considerations, DDReg helps sponsors develop more structured and decision-focused RWE strategies for evolving global regulatory environments.
Conclusion
DARWIN EU is helping establish RWE as a more structured component of European medicines regulation. Its expanding network of data partners, growing study portfolio and connection with the European Health Data Space are strengthening the infrastructure available for evidence generation.
For pharmaceutical companies, this evolution makes RWE regulatory strategy increasingly relevant across development, regulatory assessment and post-authorisation activities. The ability to connect real-world data with clearly defined regulatory questions will be an important part of evidence planning in the evolving European regulatory landscape.
Frequently Asked Questions
DARWIN EU (Data Analysis and Real-World Interrogation Network) is an EMA-led network that uses real-world healthcare data to generate evidence supporting regulatory and public health questions across the medicine lifecycle.
DARWIN EU enables structured analysis of real-world data to generate evidence on medicine use, safety, effectiveness, and disease epidemiology. This evidence can complement clinical trial data and contribute to regulatory assessments and decisions where relevant.
The expansion makes real-world evidence (RWE) increasingly relevant to pharmaceutical development and regulatory planning. Companies need to consider data availability, data quality, study design, and the specific regulatory question when developing an RWE regulatory strategy.
The European Health Data Space (EHDS) is intended to strengthen access to and use of health data, including for secondary purposes. DARWIN EU provides an established infrastructure for generating RWE and is expected to support the evolving European health-data ecosystem.